Business
Exopharm (ASX:EX1) share price plunges 17% after animal testing results
The Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinical data from its osteoarthritis animal study, showing its two regenerative medical products had no effect on the rats studied.
At the time of writing, the Exopharm share price is down 15.7%, trading at 59 cents after hitting an intraday low of 55 cents.
Exopharm is a biopharmaceutical company focused on developing regenerative medicine. It’s currently investigating the therapeutic potential of two products, Plexaris and Cevaris, in treating osteoarthritis.
The company also aims to commercialise exosomes as therapeutic agents. Exosomes are membraneous structures that allow cells to communicate and have the potential to restore dying…
-
Noosa News22 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference
-
Business21 hours agoDicker Data rides the AI trend to double digit growth
-
Noosa News22 hours agoBob Katter threatens Channel 9 journalist for asking question on family heritage
-
Noosa News22 hours agoPolice search Bli Bli property as homicide team called in for missing Brisbane man